Sign in
Taking peopleNo phase

Cygnum device added to aortic aneurysm repair surgery

Tests the Cygnum device alongside standard repair in people with abdominal aortic aneurysm.

Key facts

Who runs it
Life Seal Vascular Inc.
Where
New Zealand1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
First-In-Human Study Evaluating Aneurysm Sac Lining in AAA Patients
Status
Recruiting
People taking part
15 people, planned
Started
26 Nov 2025
Expected to end
Sept 2028
Type of study
Interventional
Treatments tested
  • Cygnum Aneurysm Sac Management Device (ASMD)
Record updated
9 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an abdominal aortic aneurysm (a bulge in the main belly artery) who will have repair through the blood vessels (EVAR). The Cygnum device will be placed along with the standard repair.

Age
18 years or older
Sex
All sexes
Disease stage
Aneurysm sac at least 5.5cm (2.2 in) wide in males and at least 5.0cm (2 in) in females. Maximum blood flow channel 50mm or less. The anatomy must allow EVAR with the commercial devices used. ASA grade 1 to 3 (a fitness score before anaesthesia).
Earlier treatment
No earlier surgery or EVAR repair for the aneurysm.

Main reasons for not taking part

  • Ruptured, leaking, inflamed or infected aneurysm
  • Life expectancy under 2 years
  • Heart attack, major heart surgery, mini-stroke or stroke in the 90 days before the procedure
  • Serum creatinine 180 µmol/L (2.04 mg/dL) or higher, or a bleeding or clotting disorder
  • Pregnant or planning pregnancy, or connective tissue disease such as Marfan Syndrome

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Patient can understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent
  • Patient is willing to complete the follow-up according to the requirements of the protocol
  • Patient AAA anatomy complies with "instructions for use" for commercial EVAR devices used
  • ≥18 years old
  • Abdominal aortic aneurysm with sac diameter ≥ 5.5cm in males and ≥ 5.0cm in females
  • Maximum blood flow luminal diameter ≤ 50mm
  • Eligible for endovascular aneurysm repair based on anatomical considerations, such as adequate iliac/femoral access
  • Patient is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive

Who cannot take part

  • Concomitant Common Iliac Artery aneurysms ≥ 25mm
  • Already participating in an investigational drug or device study
  • Previous surgical or EVAR repair for AAA
  • Myocardial infarction and/or major heart surgery ≤ 90 days prior to the procedure
  • Transient Ischemic Attack or stroke ≤ 90 days prior to the procedure
  • Unstable angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia or valvular disease ≤ 30 days prior to the procedure
  • Known allergy or contraindication to any study device material
  • Coagulopathy or uncontrolled bleeding disorder
  • Connective tissue diseases (e.g., Marfan Syndrome)
  • Aneurysmal or dissected disease of the descending thoracic aorta
  • Serum creatinine level ≥ 180 µmol/L
  • Life expectancy <2 years
  • Ruptured, leaking, inflammatory or mycotic aneurysm
  • Unsuitable vascular anatomy that may interfere with device introduction or deployment, in the opinion of the investigator
  • Unable or unwilling to comply with study follow-up requirements
  • Patients of childbearing potential who are pregnant or planning to become pregnant during the course of the study
  • Patient has other medical, social or psychological problems that, in the opinion of the investigator, study involvement would not be in their best interest

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the safety and feasibility of the Cygnum Aneurysm Sac Management Device in patients with abdominal aortic aneurysms treated with endovascular aneurysm repair (EVAR). The main questions it aims to answer are:

Read full original descriptionShow less

1. Is the Cygnum device safe when used adjunctively with standard EVAR endografts? 2. Does it effectively reduce or prevent type II endoleaks by managing the aneurysm sac?

Participants will:

1. Undergo EVAR with adjunctive implantation of the Cygnum device 2. Have follow-up imaging (e.g., CT scans) and clinical assessments to evaluate device position and sac behavior over time

The group in the trial

  • Cygnum ASMD ArmTreatment being tested

    Treatment: Cygnum Aneurysm Sac Management Device (ASMD)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Aneurysm SaC ManagemENt Device for Abdominal Aortic Aneurysms First-in-Human (ASCEND) Study
Plain-language title
Cygnum device added to aortic aneurysm repair surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
9 December 2025